Cereblon调节剂iberdomide诱导转录因子Ikaros和Aiolos降解:健康志愿者的免疫调节及对系统性红斑狼疮的相关性
在SLE患者外周血单个核细胞中,CRBN、IKZF1和IKZF3 mRNA表达显著高于健康志愿者;iberdomide降低B细胞、T细胞和单核细胞中Ikaros和Aiolos蛋白水平;56名健康志愿者单次口服iberdomide 0.3-6 mg后细胞内Aiolos降低、CD19+ B细胞绝对值降低、IL-2升高、IL-1β降低。
要点
- SLE患者PBMC中CRBN、IKZF1、IKZF3 mRNA分别较健康志愿者高1.5倍、2.1倍、4.1倍
- iberdomide在SLE PBMC培养中抑制抗dsDNA和抗磷脂自身抗体产生,IC50≈10 nM
- 健康志愿者单次0.3-6 mg iberdomide降低Aiolos、B细胞,升高IL-2、降低IL-1β
核心结论
- 这些发现证明iberdomide具有药效学活性,并支持其进一步临床开发用于治疗SLE。
研究设计与样本
- 在SLE患者细胞和一项1期健康志愿者研究中研究cereblon(CRBN)调节剂iberdomide(CC-220)的药理学。
- 56名健康志愿者随机接受单次剂量iberdomide(0.03-6 mg,七个队列中每队列n=6)或安慰剂(每队列n=2)。
- 在SLE患者和健康志愿者的外周血单个核细胞(PBMC)中检测CRBN、IKZF1和IKZF3基因表达。
- 用Western blot和流式细胞术检测Ikaros和Aiolos蛋白水平。
- 在iberdomide处理7天的SLE PBMC培养中检测抗dsDNA和抗磷脂自身抗体。
主要发现
- SLE患者PBMC较健康志愿者CRBN mRNA高1.5倍、IKZF1高2.1倍、IKZF3高4.1倍。
- iberdomide显著降低B细胞、T细胞和单核细胞中Ikaros和Aiolos蛋白水平。
- 在SLE PBMC培养中,iberdomide抑制抗dsDNA和抗磷脂自身抗体产生(IC50≈10 nM)。
- 健康志愿者单次0.3-6 mg iberdomide使细胞内Aiolos降低(B细胞最低平均为基线的≈12%-28%;T细胞≈0%-33%),CD19+ B细胞绝对值降低,IL-2升高,IL-1β降低。
关键数值与推荐
- SLE患者PBMC中CRBN mRNA为健康志愿者的1.5倍、IKZF1为2.1倍、IKZF3为4.1倍。
- iberdomide抑制SLE PBMC培养中抗dsDNA和抗磷脂自身抗体产生的IC50≈10 nM。
- 健康志愿者单次0.3-6 mg iberdomide后B细胞中Aiolos最低平均为基线的≈12%-28%,T细胞为≈0%-33%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: IKZF1 and IKZF3 (encoding transcription factors Ikaros and Aiolos) are susceptibility loci for systemic lupus erythematosus (SLE). The pharmacology of iberdomide (CC-220), a cereblon (CRBN) modulator targeting Ikaros and Aiolos, was studied in SLE patient cells and in a phase 1 healthy volunteer study. METHODS: CRBN, IKZF1 and IKZF3 gene expression was measured in peripheral blood mononuclear cells (PBMC) from patients with SLE and healthy volunteers. Ikaros and Aiolos protein levels were measured by Western blot and flow cytometry. Anti-dsDNA and anti-phospholipid autoantibodies were measured in SLE PBMC cultures treated for 7 days with iberdomide. Fifty-six healthy volunteers were randomised to a single dose of iberdomide (0.03-6 mg, n=6 across seven cohorts) or placebo (n=2/cohort). CD19+ B cells, CD3+ T cells and intracellular Aiolos were measured by flow cytometry. Interleukin (IL)-2 and IL-1β production was stimulated with anti-CD3 and lipopolysaccharide, respectively, in an ex vivo whole blood assay. RESULTS: SLE patient PBMCs expressed significantly higher CRBN (1.5-fold), IKZF1 (2.1-fold) and IKZF3 (4.1-fold) mRNA levels compared with healthy volunteers. Iberdomide significantly reduced Ikaros and Aiolos protein levels in B cells, T cells and monocytes. In SLE PBMC cultures, iberdomide inhibited anti-dsDNA and anti-phospholipid autoantibody production (IC50 ≈10 nM). Single doses of iberdomide (0.3-6 mg) in healthy volunteers decreased intracellular Aiolos (minimum mean per cent of baseline: ≈12%-28% (B cells); ≈0%-33% (T cells)), decreased absolute CD19+ B cells, increased IL-2 and decreased IL-1β production ex vivo. CONCLUSIONS: These findings demonstrate pharmacodynamic activity of iberdomide and support its further clinical development for the treatment of SLE. TRIAL REGISTRATION NUMBER: NCT01733875; Results.
引用
- Schafer PH, Ye Y, Wu L, et al. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. Ann Rheum Dis. 2018. PMID: 29945920. doi:10.1136/annrheumdis-2017-212916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。